doi:10.1111/j.2042-7158.1969.tb08372.x.[Crossref], [Web of Science ] , [Google Scholar])
About 10%-25% of patients with NAFLD will develop non-alcoholic steatohepatitis (NASH), which increases the risk of liver cirrhosis or liver cancer (185)
Safety, Eligibility, and When to Discuss This with Your Provider GLP-1 medications carry known side effects including nausea, vomiting, and gastrointestinal distress
But at a time when we should be promoting health care access, the health plan for New York City employees recently made a surprising decision with far-reaching repercussions: they announced that they will discontinue coverage of GLP-1 weight loss medicines for its 400,000 public employees
[DOI] [PubMed] [Google Scholar] 152.Wu H, Li M, Shao X, An Z, Du J, Yin H, et al